Daily Management Review

FTSE 100 Demonstrates Poor Performance


04/28/2016


The sinking list of FTSE 100 casts different results on different firms.



FTSE 100 Demonstrates Poor Performance
Among other index, the FTSE 100 recently exhibited poor performances which were at the verge of sinking, while Standard Chartered was counted in with the “top performers” for the investors agreed on its “ongoing turnaround”.
 
Even though the company saw a fifty nine percent profit drop earlier this week, while “commodity prices, volatility in Chinese markets and weak emerging market sentiment” continued to be depressing, the investors were “pleased” to see a drop in “loan impairments”. In a comment the Head of Equity Research at Steve Clayton, Hargreaves Lansdown, said:
 “If the bank can hit the 10% return on equity target, and pay out half of earnings as a dividend, then an attractive yield may one day be possible, given the shares are trading far below book value. However, getting there will be easier said than done”.
 
Moreover, BP also did well in the latter half of the day after losing a “$485m” in the first quarter. As per the firm, the low prices of oil were cause of its bleak performance; although the Chief Executive at BP, Bob Dudley thinks:
"Market fundamentals continue to suggest that the combination of robust demand and weak supply growth will move global oil markets closer into balance by the end of the year”.
 
AstraZeneca faced a lot of “pressure” following its attempt of spreading “a double whammy of positive news”, for prior to the market’s opening, the company announced that “the US Food and Drug Administration had approved its Bevespi Aerosphere inhalation aerosol for treating patients with chronic obstructive pulmonary disease”. Digitallook explains:
“The product - glycopyrrolate and formoterol fumarate - is used for the long-term, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema”.
 
However, later on AstraZeneca informed that Ironwood Pharmaceuticals were buying the U.S. Market Rights for “a newly-approved gout drug - Zurampic, or lesinurad”. The deal struck between both the companies enables Ironwood to “sell both Zurampic to treat high levels of uric acid in the blood of gout patients, and a fixed-dose combination of lesinurad and allopurinol”.
 
References:
http://www.digitallook.com/







Science & Technology

Motorola’s New Patent Will Self-Heal A Cracked Smartphone Screen

Auto Parts Out Of Wood Is What Japan Is Looking At Making

Security Firm Claims Hotel Guests Across Europe Were Targeted By Russia-Linked Hackers

World’s First Genetically-Modified Animal To Enter Food Supply Is Salmon

In The Future, UBS Analyst Says, Multiple Planes Could Be Operated From The Ground By Today’s Pilots

Will Germany save diesel?

How China became a pioneer of the solar industry

CNBC: Intel leaves the wearable gadgets market

Oculus Rift falls in price…again

Ukraine Police Official Says Likely Cover For Malware Installation Was Global Cyber Attack: Reuters

World Politics

World & Politics

Russia surpasses Saudi Arabia in oil production

China counts losses from sanctions against the DPRK

OCP Group Vs South African Courts: A storm is brewing on international maritime trade

Britain to conduct a study on labor migration after Brexit

CNN: Rex Tillerson may leave the post of US Secretary of State

Its South China Sea Territory Being Protected By Indonesia From 'Foreign' Threats

A Swarm-Like Attack From North Korea Could ‘Overwhelm’ South Korea's THAAD Missile Shield

Powerty in Italy tripled in 10 years